Rapeseed cytoplasm gives advantage in wild relatives and complicates genetically modified crop biocontainment.

Biocontainment methods for genetically modified crops closest to commercial reality (chloroplast transformation, male sterility) would be compromised (in absolute terms) by seed-mediated gene flow leading to chloroplast capture. Even in these circumstances, however, it can be argued that biocontainment still represses transgene movement, with the efficacy depending on the relative frequency of seed- and pollen-mediated gene flow. In this study, we screened for crop-specific chloroplast markers from rapeseed (Brassica napus) amongst sympatric and allopatric populations of wild B. oleracea in natural cliff-top populations and B. rapa in riverside and weedy populations. We found only modest crop chloroplast presence in wild B. oleracea and in weedy B. rapa, but a surprisingly high incidence in sympatric (but not in allopatric) riverside B. rapa populations. Chloroplast inheritance models indicate that elevated crop chloroplast acquisition is best explained if crop cytoplasm confers selective advantage in riverside B. rapa populations. Our results therefore imply that chloroplast transformation may slow transgene recruitment in two settings, but actually accelerate transgene spread in a third. This finding suggests that the appropriateness of chloroplast transformation for biocontainment policy depends on both context and geographical location.

Systems and Synthetic biology: tackling genetic networks and complex diseases.

In the era of post-genomic research two new disciplines, Systems and Synthetic biology, act in a complementary way to shed light on the ever-increasing amount of data produced by novel high-throughput techniques. Systems biology aims at developing a formal understanding of biological processes through the development of quantitative mathematical models (bottom-up approach) and of 'reverse engineering' (top-down approach), whose aim is to infer the interactions among genes and proteins from experimental observations (gene regulatory networks). Synthetic biology on the other hand uses mathematical models to design novel biological 'circuits' (synthetic networks) able to perform specific tasks (for example, periodic expression of a gene of interest), or able to change the behavior of a biological process in a desired way (for example, modify metabolism to produce a specific compound of interest). The use of a pioneering approach that combines biology and engineering, to describe and/or invent new behaviors, could represent a valuable resource for studying complex diseases and design novel therapies. The identification of regulatory networks will help in identifying hundreds of genes that are responsible for most genetic diseases and that could serve as a starting point for therapeutic intervention. Here we present some of the main genetics and medical applications of these two emerging fields.

[Abrupt shift to zolpidem, a new imidazopyridine hypnotic, in insomniac patients previously treated with benzodiazepine hypnotics]. / Passaggio ex-abrupto a zolpidem, nuovo ipnotico imidazopiridinico, in pazienti insonni già in trattamento con ipnotici benzodiazepinici.

Zolpidem is a new imidazopyridine hypnotic with a pharmacological profile substantially different from benzodiazepines. In this observational multicenter study the possibility of shifting to zolpidem (10 mg at N1, 15 or 20 after N1) insomniac patients previously taking (for at least 15 days and not longer than 3 months) standard posology of triazolam (0.125-0.25 mg), lorazepam (1 mg) or lormetazepam (1 mg) was assessed. For ethical reasons the patients were mandatorily to be insomniacs despite their taking hypnotics or not tolerating them. Patients enrolled were 299 of whom 276 evaluable (139 males and 136 females; mean age 48.67 +/- 14.64, range 18-83). Study duration was 7 nights with visits at N0 (baseline), N1 (after 1st night), N3 (after 3rd night) and N7 (final evaluation); on each visit the Saint Mary Hospital Sleep Questionnaire and the benzodiazepine withdrawal symptom's rating scale were administered; moreover, after N7, investigators were asked a judgement of feasibility of such a shift. In 229 (83.5%) out of 274 patients such a shift to zolpidem was considered successfully (no occurrence of symptoms and/or signs of previously taken hypnotic withdrawal); in the remaining 45 patients, just 17 (6.2%) seemed to be real unsuccessful cases (reactions mild and transient, anyhow). In conclusion abrupt shift to zolpidem appeared to be largely feasible in the patients studied.